[
  {
    "section": "section:1",
    "title": "Phase I study of bortezomib and cetuximab in patients with solid tumours expressing epidermal growth factor receptor"
  },
  {
    "section": "section:2",
    "title": "PATIENTS AND METHODS"
  },
  {
    "section": "section:3",
    "title": "Study design"
  },
  {
    "section": "section:3",
    "title": "Patient eligibility"
  },
  {
    "section": "section:3",
    "title": "Treatment schedule"
  },
  {
    "section": "section:3",
    "title": "Bortezomib dose escalation"
  },
  {
    "section": "section:3",
    "title": "Efficacy assessment and follow-up care"
  },
  {
    "section": "section:3",
    "title": "Statistical methods"
  },
  {
    "section": "section:2",
    "title": "RESULTS"
  },
  {
    "section": "section:3",
    "title": "Patient characteristics"
  },
  {
    "section": "section:3",
    "title": "Bortezomib dose-escalation findings"
  },
  {
    "section": "section:3",
    "title": "Toxicity assessment"
  },
  {
    "section": "section:3",
    "title": "Tumour response"
  },
  {
    "section": "section:2",
    "title": "DISCUSSION"
  },
  {
    "section": "section:2",
    "title": "Table 1 Patient characteristics"
  },
  {
    "section": "section:2",
    "title": "Table 2 Grade ges3 toxicity for each bortezomib dose level"
  },
  {
    "section": "section:2",
    "title": "Table 3 EGFR staining and response"
  },
  {
    "section": "section:2",
    "title": "ACKNOWLEDGEMENTS"
  },
  {
    "section": "section:2",
    "title": "REFERENCES"
  }
]